{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:57:19Z","timestamp":1778342239276,"version":"3.51.4"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13048-019-0546-9","type":"journal-article","created":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T05:02:44Z","timestamp":1564203764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Anti-proliferative effects of mesenchymal stem cells (MSCs) derived from multiple sources on ovarian cancer cell lines: an in-vitro experimental study"],"prefix":"10.1186","volume":"12","author":[{"given":"C.","family":"Khalil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Azar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tawk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Habbouche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Salameh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Alaaeddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,27]]},"reference":[{"key":"546_CR1","unstructured":"Statistics [Internet]. Ovarian Cancer Research Fund Alliance. [cited 2018 May 8]. Available from: \n                              https:\/\/ocrfa.org\/patients\/about-ovarian-cancer\/statistics\/"},{"key":"546_CR2","unstructured":"CD44+\/CD24\u2212 ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival | SpringerLink [Internet]. [cited 2018 Feb 5]. Available from: \n                              https:\/\/link.springer.com\/article\/10.1007\/s10585-012-9482-4"},{"key":"546_CR3","unstructured":"Statistics [Internet]. Ovarian Cancer Research Fund Alliance. [cited 2018 Feb 11]. Available from: \n                              https:\/\/ocrfa.org\/patients\/about-ovarian-cancer\/statistics\/"},{"key":"546_CR4","doi-asserted-by":"crossref","unstructured":"European cancer mortality predictions for the year 2018 with focus on colorectal cancer | Annals of Oncology | Oxford Academic [Internet]. [cited 2019 Jan 27]. Available from: \n                              https:\/\/academic.oup.com\/annonc\/article\/29\/4\/1016\/4935197","DOI":"10.1093\/annonc\/mdy033"},{"key":"546_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/1756-0500-7-254","volume":"7","author":"A Schellenberg","year":"2014","unstructured":"Schellenberg A, Mauen S, Koch CM, Jans R, de Waele P, Wagner W. Proof of principle: quality control of therapeutic cell preparations using senescence-associated DNA-methylation changes. BMC Research Notes. 2014;7:254.","journal-title":"BMC Research Notes"},{"issue":"4","key":"546_CR6","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.3892\/mmr.2015.4062","volume":"12","author":"B Mckinnon","year":"2015","unstructured":"Mckinnon B, Mueller MD, Nirgianakis K, Bersinger NA. Comparison of ovarian cancer markers in endometriosis favours HE4 over CA125. Mol Med Rep. 2015;12(4):5179\u201384.","journal-title":"Mol Med Rep"},{"issue":"5","key":"546_CR7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1200\/JCO.2006.06.4907","volume":"25","author":"HD Homesley","year":"2007","unstructured":"Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a gynecologic oncology group study. J Clin Oncol. 2007;25(5):526\u201331.","journal-title":"J Clin Oncol"},{"issue":"16","key":"546_CR8","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1200\/JCO.2009.26.8326","volume":"28","author":"MA Powell","year":"2010","unstructured":"Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. J Clin Oncol. 2010;28(16):2727\u201331.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"546_CR9","doi-asserted-by":"publisher","first-page":"TPS5609","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS5609","volume":"36","author":"RT Penson","year":"2018","unstructured":"Penson RT, Moore KN, Herzog TJ, Burger RA, Freedman LS, Lowenton-Spier N, et al. Clinical trial in progress: A study of VB-111 combined with paclitaxel vs. paclitaxel for treatment of recurrent platinum-resistant ovarian cancer (OVAL, VB-111-701\/GOG-3018). JCO. 2018;36(15_suppl):TPS5609.","journal-title":"JCO"},{"issue":"36","key":"546_CR10","doi-asserted-by":"publisher","first-page":"24304","DOI":"10.18632\/oncotarget.24368","volume":"9","author":"ES Han","year":"2018","unstructured":"Han ES, Wen W, Dellinger TH, Wu J, Lu SA, Jove R, et al. Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer. Oncotarget. 2018;9(36):24304\u201319.","journal-title":"Oncotarget."},{"key":"546_CR11","unstructured":"Carboplatin\/Paclitaxel Induction in Ovarian Cancer: The Finer Points | Cancer Network [Internet]. [cited 2018 Nov 5]. Available from: \n                              http:\/\/www.cancernetwork.com\/ovarian-cancer\/carboplatinpaclitaxel-induction-ovarian-cancer-finer-points"},{"key":"546_CR12","unstructured":"PDQ Adult Treatment Editorial Board. Endometrial Cancer Treatment (PDQ\u00ae): Health Professional Version. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002 [cited 2019 Jan 27]. Available from: \n                              http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK65829\/"},{"key":"546_CR13","unstructured":"Uterine sarcomas - Mbatani - 2018 - International Journal of Gynecology & Obstetrics - Wiley Online Library [Internet]. [cited 2019 Jan 27]. Available from: \n                              https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/full\/10.1002\/ijgo.12613"},{"issue":"1","key":"546_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ygyno.2013.07.097","volume":"131","author":"JA Rauh-Hain","year":"2013","unstructured":"Rauh-Hain JA, Diver EJ, Clemmer JT, Bradford LS, Clark RM, Growdon WB, et al. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol. 2013;131(1):46\u201351.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"546_CR15","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1002\/cncr.20256","volume":"100","author":"E Brown","year":"2004","unstructured":"Brown E, Stewart M, Rye T, Al-Nafussi A, Williams ARW, Bradburn M, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer. 2004;100(10):2148\u201353.","journal-title":"Cancer."},{"issue":"2","key":"546_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1525-1438.2006.00760.x","volume":"17","author":"MS Mano","year":"2007","unstructured":"Mano MS, Rosa DD, Azambuja E, Ismael G, Braga S, D\u2019Hondt V, et al. Current management of ovarian carcinosarcoma. Int J Gynecol Cancer. 2007;17(2):316\u201324.","journal-title":"Int J Gynecol Cancer"},{"key":"546_CR17","doi-asserted-by":"publisher","first-page":"175883591876823","DOI":"10.1177\/1758835918768232","volume":"10","author":"JA Ledermann","year":"2018","unstructured":"Ledermann JA. First-line treatment of ovarian cancer: questions and controversies to address. Ther Adv Med Oncol. 2018;10:1758835918768232.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"546_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2018.05.020","volume":"150","author":"K Lindemann","year":"2018","unstructured":"Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, et al. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecol Oncol. 2018;150(2):239\u201346.","journal-title":"Gynecol Oncol"},{"issue":"5411","key":"546_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1126\/science.284.5411.143","volume":"284","author":"MF Pittenger","year":"1999","unstructured":"Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143\u20137.","journal-title":"Science."},{"key":"546_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/B978-0-12-809880-6.00014-X","volume-title":"Principles of Regenerative Medicine","author":"Zulma Gazit","year":"2019","unstructured":"Gazit Z, Pelled G, Sheyn D, Yakubovich DC, Gazit D. Chapter 14 - Mesenchymal Stem Cells. In: Atala A, Lanza R, Mikos AG, Nerem R, editors. Principles of Regenerative Medicine (Third Edition) [Internet]. Boston: Academic Press; 2019. p. 205\u2013218. [cited 2019 Jan 27]. Available from: \n                              http:\/\/www.sciencedirect.com\/science\/article\/pii\/B978012809880600014X"},{"issue":"12","key":"546_CR21","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.exphem.2009.09.004","volume":"37","author":"J Kim","year":"2009","unstructured":"Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol. 2009;37(12):1445\u201353.","journal-title":"Exp Hematol"},{"issue":"1","key":"546_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/mt.2011.211","volume":"20","author":"DJ Prockop","year":"2012","unstructured":"Prockop DJ, Oh JY. Mesenchymal stem\/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012;20(1):14\u201320.","journal-title":"Mol Ther"},{"key":"546_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.canlet.2017.11.025","volume":"414","author":"A Mohr","year":"2018","unstructured":"Mohr A, Zwacka R. The future of mesenchymal stem cell-based therapeutic approaches for cancer - from cells to ghosts. Cancer Lett. 2018;414:239\u201349.","journal-title":"Cancer Lett"},{"issue":"5","key":"546_CR24","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00277-018-3250-8","volume":"97","author":"I Stoma","year":"2018","unstructured":"Stoma I, Karpov I, Krivenko S, Iskrov I, Milanovich N, Koritko A, et al. Mesenchymal stem cells transplantation in hematological patients with acute graft-versus-host disease: characteristics and risk factors for infectious complications. Ann Hematol. 2018;97(5):885\u201391.","journal-title":"Ann Hematol"},{"issue":"3","key":"546_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.stem.2015.02.019","volume":"16","author":"Y Kfoury","year":"2015","unstructured":"Kfoury Y, Scadden DT. Mesenchymal cell contributions to the stem cell niche. Cell Stem Cell. 2015;16(3):239\u201353.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"546_CR26","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1634\/stemcells.2005-0342","volume":"24","author":"S Kern","year":"2006","unstructured":"Kern S, Eichler H, Stoeve J, Kl\u00fcter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24(5):1294\u2013301.","journal-title":"Stem Cells"},{"issue":"4","key":"546_CR27","first-page":"221","volume":"119","author":"M Matuskova","year":"2018","unstructured":"Matuskova M, Durinikova E, Altaner C, Kucerova L. Genetically engineered mesenchymal stromal cells in cancer gene therapy. Bratisl Lek Listy. 2018;119(4):221\u20133.","journal-title":"Bratisl Lek Listy"},{"key":"546_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1478-811X-9-12","volume":"9","author":"R Hass","year":"2011","unstructured":"Hass R, Kasper C, B\u00f6hm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011;9:12.","journal-title":"Cell Commun Signal"},{"key":"546_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4939-2938-2_4","volume":"1340","author":"N Mahmoudifar","year":"2015","unstructured":"Mahmoudifar N, Doran PM. Mesenchymal stem cells derived from human adipose tissue. Methods Mol Biol. 2015;1340:53\u201364.","journal-title":"Methods Mol Biol"},{"issue":"5","key":"546_CR30","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10616-012-9428-3","volume":"64","author":"TT Sibov","year":"2012","unstructured":"Sibov TT, Severino P, Marti LC, Pavon LF, Oliveira DM, Tobo PR, et al. Mesenchymal stem cells from umbilical cord blood: parameters for isolation, characterization and adipogenic differentiation. Cytotechnology. 2012;64(5):511\u201321.","journal-title":"Cytotechnology."},{"key":"546_CR31","doi-asserted-by":"crossref","unstructured":"Shi Q, Gao J, Jiang Y, Sun B, Lu W, Su M, et al. Differentiation of human umbilical cord Wharton\u2019s jelly-derived mesenchymal stem cells into endometrial cells. Stem Cell Res Ther [Internet]. 2017:8 Available from: \n                              https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5667478\/\n                              \n                           .","DOI":"10.1186\/s13287-017-0700-5"},{"issue":"1","key":"546_CR32","first-page":"1245","volume":"17","author":"Y-L Zhou","year":"2019","unstructured":"Zhou Y-L, Li Y-M, He W-T. Oxygen-laden mesenchymal stem cells enhance the effect of gastric cancer chemotherapy in vitro. Oncol Lett. 2019;17(1):1245\u201352.","journal-title":"Oncol Lett"},{"issue":"6","key":"546_CR33","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/jemt.23236","volume":"82","author":"X Li","year":"2019","unstructured":"Li X, Li Z. Effects of human umbilical cord mesenchymal stem cells on co-cultured ovarian carcinoma cells. Microsc Res Tech. 2019;82(6):898\u2013902.","journal-title":"Microsc Res Tech"},{"issue":"5","key":"546_CR34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3748\/wjg.v25.i5.567","volume":"25","author":"R Serhal","year":"2019","unstructured":"Serhal R, Saliba N, Hilal G, Moussa M, Hassan GS, El Atat O, et al. Effect of adipose-derived mesenchymal stem cells on hepatocellular carcinoma: in vitro inhibition of carcinogenesis. World J Gastroenterol. 2019;25(5):567\u201383.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"546_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11515-018-1513-3","volume":"13","author":"D Gao","year":"2018","unstructured":"Gao D, Mittal V, Ban Y, Lourenco AR, Yomtoubian S, Lee S. Metastatic tumor cells - genotypes and phenotypes. Front Biol (Beijing). 2018;13(4):277\u201386.","journal-title":"Front Biol (Beijing)"},{"issue":"2","key":"546_CR36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/cancers11020185","volume":"11","author":"Catharina Melzer","year":"2019","unstructured":"Melzer C, von der Ohe J, Hass R. In Vivo Cell Fusion between Mesenchymal Stroma\/Stem-Like Cells and Breast Cancer Cells. Cancers (Basel). 2019;11(2).","journal-title":"Cancers"},{"issue":"17","key":"546_CR37","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.7150\/jca.25376","volume":"9","author":"J Zhou","year":"2018","unstructured":"Zhou J, Tan X, Tan Y, Li Q, Ma J, Wang G. Mesenchymal stem cell derived exosomes in Cancer progression, metastasis and drug delivery: a comprehensive review. J Cancer. 2018;9(17):3129\u201337.","journal-title":"J Cancer"},{"issue":"3","key":"546_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/1061186X.2016.1258569","volume":"25","author":"Y-J Liu","year":"2017","unstructured":"Liu Y-J, Dou X-Q, Wang F, Zhang J, Wang X-L, Xu G-L, et al. IL-4R\u03b1 aptamer-liposome-CpG oligodeoxynucleotides suppress tumour growth by targeting the tumour microenvironment. J Drug Target. 2017;25(3):275\u201383.","journal-title":"J Drug Target"},{"issue":"11","key":"546_CR39","doi-asserted-by":"publisher","first-page":"e0207593","DOI":"10.1371\/journal.pone.0207593","volume":"13","author":"AT Alshareeda","year":"2018","unstructured":"Alshareeda AT, Rakha E, Alghwainem A, Alrfaei B, Alsowayan B, Albugami A, et al. The effect of human placental chorionic villi derived mesenchymal stem cell on triple-negative breast cancer hallmarks. PLoS One. 2018;13(11):e0207593.","journal-title":"PLoS One"},{"issue":"1","key":"546_CR40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12307-010-0041-8","volume":"3","author":"X Ling","year":"2010","unstructured":"Ling X, Marini F, Konopleva M, Schober W, Shi Y, Burks J, et al. Mesenchymal stem cells overexpressing IFN-\u03b2 inhibit breast Cancer growth and metastases through Stat3 signaling in a syngeneic tumor model. Cancer Microenviron. 2010;3(1):83\u201395.","journal-title":"Cancer Microenviron"},{"key":"546_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.omto.2018.12.003","volume":"12","author":"R Mooney","year":"2019","unstructured":"Mooney R, Majid AA, Batalla-Covello J, Machado D, Liu X, Gonzaga J, et al. Enhanced delivery of oncolytic adenovirus by neural stem cells for treatment of metastatic ovarian Cancer. Mol Ther Oncolytics. 2019;12:79\u201392.","journal-title":"Mol Ther Oncolytics"},{"issue":"4","key":"546_CR42","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/S0002-9440(10)64398-2","volume":"161","author":"G Kristiansen","year":"2002","unstructured":"Kristiansen G, Denkert C, Schl\u00fcns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian Cancer and is a new independent prognostic marker of patient survival. Am J Pathol. 2002;161(4):1215\u201321.","journal-title":"Am J Pathol"},{"issue":"3","key":"546_CR43","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/jcp.27581","volume":"234","author":"V Tarhriz","year":"2019","unstructured":"Tarhriz V, Bandehpour M, Dastmalchi S, Ouladsahebmadarek E, Zarredar H, Eyvazi S. Overview of CD24 as a new molecular marker in ovarian cancer. J Cell Physiol. 2019;234(3):2134\u201342.","journal-title":"J Cell Physiol"},{"issue":"4","key":"546_CR44","first-page":"1716","volume":"46","author":"Y Tao","year":"2018","unstructured":"Tao Y, Li H, Huang R, Mo D, Zeng T, Fang M, et al. Clinicopathological and prognostic significance of Cancer stem cell markers in ovarian Cancer patients: evidence from 52 studies. CPB. 2018;46(4):1716\u201326.","journal-title":"CPB."},{"key":"546_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fbioe.2019.00009","volume":"7","author":"P Mancuso","year":"2019","unstructured":"Mancuso P, Raman S, Glynn A, Barry F, Murphy JM. Mesenchymal stem cell therapy for osteoarthritis: the critical role of the cell Secretome. Front Bioeng Biotechnol. 2019;7:9.","journal-title":"Front Bioeng Biotechnol"},{"issue":"3","key":"546_CR46","first-page":"230","volume":"12","author":"S Sriramulu","year":"2018","unstructured":"Sriramulu S, Banerjee A, Di Liddo R, Jothimani G, Gopinath M, Murugesan R, et al. Concise review on clinical applications of conditioned medium derived from human umbilical cord-mesenchymal stem cells (UC-MSCs). Int J Hematol Oncol Stem Cell Res. 2018;12(3):230\u20134.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"4","key":"546_CR47","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/term.2806","volume":"13","author":"TNA Gunawardena","year":"2019","unstructured":"Gunawardena TNA, Mohammad TR, Abdullah BJJ, Abu Kasim NH. Conditioned media serived from mesenchymal stem cell cultures: the next generation for regenerative medicine. J Tissue Eng Regen Med. 2019;13(4):569\u201386.","journal-title":"J Tissue Eng Regen Med"},{"issue":"7742","key":"546_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/d41586-019-00490-6","volume":"566","author":"AI Caplan","year":"2019","unstructured":"Caplan AI. Medicinal signalling cells: they work, so use them. Nature. 2019;566(7742):39.","journal-title":"Nature."},{"key":"546_CR49","doi-asserted-by":"crossref","unstructured":"Sutton MT, Fletcher D, Episalla N, Auster L, Kaur S, Gwin MC, et al. Mesenchymal Stem Cell Soluble Mediators and Cystic Fibrosis. J Stem Cell Res Ther. 2017;7(9).","DOI":"10.4172\/2157-7633.1000400"},{"issue":"Suppl 1","key":"546_CR50","first-page":"S73","volume":"11","author":"K Jalili Angourani","year":"2018","unstructured":"Jalili Angourani K, Mazhari S, Farivar S, Salman Mahini D, Rouintan A, Baghaei K. Fibroblast-myofibroblast crosstalk after exposure to mesenchymal stem cells secretome. Gastroenterol Hepatol Bed Bench. 2018;11(Suppl 1):S73\u20139.","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"546_CR51","doi-asserted-by":"crossref","unstructured":"Fernandes-Cunha GM, Na K-S, Putra I, Lee HJ, Hull S, Cheng Y-C, et al. Corneal Wound Healing Effects of Mesenchymal Stem Cell Secretome Delivered Within a Viscoelastic Gel Carrier. Stem Cells Transl Med. 2019.","DOI":"10.1002\/sctm.18-0178"},{"key":"546_CR52","doi-asserted-by":"crossref","unstructured":"Kalamegam G, Sait KHW, Ahmed F, Kadam R, Pushparaj PN, Anfinan N, et al. Human Wharton\u2019s Jelly Stem Cell (hWJSC) Extracts Inhibit Ovarian Cancer Cell Lines OVCAR3 and SKOV3 in vitro by Inducing Cell Cycle Arrest and Apoptosis. Front Oncol [Internet]. 2018;8. [cited 2019 Mar 5]. Available from: \n                              https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2018.00592\/full","DOI":"10.3389\/fonc.2018.00592"},{"issue":"1","key":"546_CR53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13048-017-0338-z","volume":"10","author":"GE B\u0119dkowska","year":"2017","unstructured":"B\u0119dkowska GE, Gacuta E, Zajkowska M, G\u0142a\u017cewska EK, Osada J, Szmitkowski M, et al. Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers. J Ovarian Res. 2017;10(1):39.","journal-title":"J Ovarian Res"},{"issue":"6","key":"546_CR54","doi-asserted-by":"crossref","first-page":"e6104","DOI":"10.1590\/1414-431x20176104","volume":"50","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Chen Q. Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer. Braz J Med Biol Res. 2017;50(6):e6104.","journal-title":"Braz J Med Biol Res"},{"key":"546_CR55","doi-asserted-by":"crossref","unstructured":"Almalki SG, Agrawal DK. Effects of matrix metalloproteinases on the fate of mesenchymal stem cells. Stem Cell Res Ther [Internet]. 2016;7(1). [cited 2019 Jul 8]. Available from: \n                              https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5016871\/","DOI":"10.1186\/s13287-016-0393-1"},{"issue":"9","key":"546_CR56","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2006-10-051060","volume":"109","author":"C Ries","year":"2007","unstructured":"Ries C, Egea V, Karow M, Kolb H, Jochum M, Neth P. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood. 2007;109(9):4055\u201363.","journal-title":"Blood."},{"issue":"6","key":"546_CR57","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s00404-012-2456-6","volume":"286","author":"X Hu","year":"2012","unstructured":"Hu X, Li D, Zhang W, Zhou J, Tang B, Li L. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. Arch Gynecol Obstet. 2012;286(6):1537\u201343.","journal-title":"Arch Gynecol Obstet"},{"issue":"3\u20134","key":"546_CR58","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/sj.bjc.6690357","volume":"80","author":"RS Boyd","year":"1999","unstructured":"Boyd RS, Balkwill FR. MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts. Br J Cancer. 1999;80(3\u20134):315\u201321.","journal-title":"Br J Cancer"},{"issue":"2","key":"546_CR59","doi-asserted-by":"publisher","first-page":"R55","DOI":"10.1530\/REP-14-0546","volume":"150","author":"L Al-Alem","year":"2015","unstructured":"Al-Alem L, Curry TE. Ovarian cancer: involvement of the matrix metalloproteinases. Reproduction. 2015;150(2):R55\u201364.","journal-title":"Reproduction."},{"issue":"1","key":"546_CR60","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1600-065X.2012.01099.x","volume":"246","author":"JA DiDonato","year":"2012","unstructured":"DiDonato JA, Mercurio F, Karin M. NF-\u03baB and the link between inflammation and cancer. Immunol Rev. 2012;246(1):379\u2013400.","journal-title":"Immunol Rev"},{"key":"546_CR61","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.3389\/fimmu.2018.02918","volume":"9","author":"P Ahechu","year":"2018","unstructured":"Ahechu P, Zozaya G, Mart\u00ed P, Hern\u00e1ndez-Lizo\u00e1in JL, Baixauli J, Unamuno X, et al. NLRP3 Inflammasome: a possible link between obesity-associated low-grade chronic inflammation and colorectal Cancer development. Front Immunol. 2018;9:2918.","journal-title":"Front Immunol"},{"issue":"12","key":"546_CR62","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1002\/pon.4316","volume":"26","author":"M Li","year":"2017","unstructured":"Li M, Kouzmina E, McCusker M, Rodin D, Boutros PC, Paige CJ, et al. Pro- and anti-inflammatory cytokine associations with major depression in cancer patients. Psychooncology. 2017;26(12):2149\u201356.","journal-title":"Psychooncology."},{"issue":"2","key":"546_CR63","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1158\/0008-5472.CAN-10-4627","volume":"72","author":"T Tanikawa","year":"2012","unstructured":"Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, N\u00fa\u00f1ez G, et al. Interleukin (IL)-10 ablation promotes tumor development, growth and metastasis. Cancer Res. 2012;72(2):420\u20139.","journal-title":"Cancer Res"},{"issue":"1","key":"546_CR64","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S1471-4906(02)00009-1","volume":"24","author":"S Mocellin","year":"2003","unstructured":"Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. Trends Immunol. 2003;24(1):36\u201343.","journal-title":"Trends Immunol"},{"issue":"Suppl 4","key":"546_CR65","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/1471-2164-15-S4-S2","volume":"15","author":"ES Acuner-Ozbabacan","year":"2014","unstructured":"Acuner-Ozbabacan ES, Engin BH, Guven-Maiorov E, Kuzu G, Muratcioglu S, Baspinar A, et al. The structural network of Interleukin-10 and its implications in inflammation and cancer. BMC Genomics. 2014;15(Suppl 4):S2.","journal-title":"BMC Genomics"},{"issue":"4","key":"546_CR66","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1590\/s0004-2803.201800000-83","volume":"55","author":"M Shokrzadeh","year":"2018","unstructured":"Shokrzadeh M, Mohammadpour A, Hoseini V, Abediankenari S, Ghassemi-Barghi N, Tabari YS. Serum cytokine of IL-2, IL-10 and IL-12 levels in patients with stomach adenocarcinoma. Arq Gastroenterol. 2018;55(4):385\u20139.","journal-title":"Arq Gastroenterol"},{"issue":"2","key":"546_CR67","doi-asserted-by":"publisher","first-page":"229","DOI":"10.30699\/ijp.13.2.229","volume":"13","author":"M Rezaeishahmirzadi","year":"2018","unstructured":"Rezaeishahmirzadi M, Motamedi Rad N, Kalantar M, Ayatollahi H, Shakeri S, Sheikhi M, et al. The Association of Gastritis and Peptic Ulcer with Polymorphisms in the inflammatory-related genes IL-4 and IL-10 in Iranian population. Iran J Pathol. 2018;13(2):229\u201336.","journal-title":"Iran J Pathol"},{"key":"546_CR68","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.biomaterials.2017.07.024","volume":"142","author":"P Guruprasath","year":"2017","unstructured":"Guruprasath P, Kim J, Gunassekaran GR, Chi L, Kim S, Park R-W, et al. Interleukin-4 receptor-targeted delivery of Bcl-xL siRNA sensitizes tumors to chemotherapy and inhibits tumor growth. Biomaterials. 2017;142:101\u201311.","journal-title":"Biomaterials."},{"issue":"17","key":"546_CR69","doi-asserted-by":"crossref","first-page":"23425","DOI":"10.18632\/oncotarget.8111","volume":"7","author":"HL Lee","year":"2016","unstructured":"Lee HL, Park MH, Song JK, Jung YY, Kim Y, Kim KB, et al. Tumor growth suppressive effect of IL-4 through p21-mediated activation of STAT6 in IL-4R\u03b1 overexpressed melanoma models. Oncotarget. 2016;7(17):23425\u201338.","journal-title":"Oncotarget."},{"issue":"6","key":"546_CR70","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/cmi.2009.53","volume":"6","author":"Z Li","year":"2009","unstructured":"Li Z, Chen L, Qin Z. Paradoxical roles of IL-4 in tumor immunity. Cell Mol Immunol. 2009;6(6):415\u201322.","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"546_CR71","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.3390\/ijms20092151","volume":"20","author":"S Proietti","year":"2019","unstructured":"Proietti S, Cucina A, Pensotti A, Biava PM, Minini M, Monti N, et al. Active fraction from embryo fish extracts induces reversion of the malignant invasive phenotype in breast Cancer through Down-regulation of TCTP and modulation of E-cadherin\/\u03b2-catenin pathway. Int J Mol Sci. 2019;20(9):2151.","journal-title":"Int J Mol Sci"},{"issue":"43","key":"546_CR72","doi-asserted-by":"publisher","first-page":"15364","DOI":"10.1073\/pnas.0406776101","volume":"101","author":"M Tuynder","year":"2004","unstructured":"Tuynder M, Fiucci G, Prieur S, Lespagnol A, G\u00e9ant A, Beaucourt S, et al. Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci U S A. 2004;101(43):15364\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"546_CR73","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/CCO.0b013e32835b7d21","volume":"25","author":"R Amson","year":"2013","unstructured":"Amson R, Karp JE, Telerman A. Lessons from tumor reversion for cancer treatment. Curr Opin Oncol. 2013;25(1):59\u201365.","journal-title":"Curr Opin Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0546-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-019-0546-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0546-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T23:10:24Z","timestamp":1595718624000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-019-0546-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,27]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["546"],"URL":"https:\/\/doi.org\/10.1186\/s13048-019-0546-9","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,27]]},"assertion":[{"value":"6 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Saint-Joseph University and the HDF Ethics Review Board approved the retrieval of all MSC collections (approval reference number: CEHDF 1142), and all patients were asked to read and approve\/sign informed consent forms prior to any participation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}